Today: 19 July 2026
Rigetti Computing Stock Price Today: RGTI Edges Up as Insider Sales Keep Focus on 108-Qubit Roadmap

Rigetti Computing Stock Price Today: RGTI Edges Up as Insider Sales Keep Focus on 108-Qubit Roadmap

NEW YORK, March 13, 2026, 4:15 PM EDT

Rigetti Computing edged up Friday, closing at $16.17, up roughly 0.6%. Shares swung from $15.90 to $17.25 during the session. New insider filings revealed recent stock sales from two executives, spotlighting the quantum-computing firm as it continues its push to translate tech breakthroughs into consistent revenue.

This timing stands out: the filings arrive barely a week after Rigetti flagged disappointing annual sales and told investors that Q1 revenue would get a bump as earlier system orders move out the door. For 2025, Rigetti logged $7.1 million in revenue. Cash, cash equivalents and available-for-sale investments totaled $589.8 million as of December’s close.

CTO David Rivas unloaded 36,719 shares on March 10 at a weighted average of $17.5201, according to a Form 4 filed this week, with the transaction noted as a required sale to cover taxes from RSUs. Another Form 4 showed CFO Jeffrey Bertelsen sold 4,270 shares, also for tax withholding, at a $17.5186 average. Bertelsen picked up options for 180,000 shares, strike price $16.99.

Rigetti’s commercial landscape is looking better, though the company’s revenue remains limited. Chief Executive Subodh Kulkarni flagged ongoing growth in on-premises system demand from government and research buyers. He highlighted an $8.4 million sale to India’s Centre for Development of Advanced Computing for a 108-qubit computer—so, a machine that operates with 108 quantum bits. Kulkarni also noted a Novera quantum processing unit, or QPU, ordered by a Japanese research group. That one is slated for delivery in April.

The roadmap remains the sticking point. Back in January, Rigetti delayed the general release of its 108-qubit Cepheus-1-108Q system to roughly the end of Q1 2026, citing the need for extra time to test and fine-tune the hardware—and to boost two-qubit gate fidelity, which tracks how precisely paired qubits can execute operations.

The stock stays stuck alongside the rest of the listed quantum companies. IonQ barely budged Friday; D-Wave Quantum slipped roughly 1.5%. Last month, Barron’s cited Cantor Fitzgerald analyst Troy Jensen, who said the Cepheus delay “doesn’t derail” Rigetti’s longer-term roadmap. Barron’s

The risk side is clear. According to Reuters financial data, Rigetti reported a net loss of $216.2 million for 2025. SEC filings from the company spell out the usual headaches: deliveries might be pushed back, orders aren’t guaranteed, government support could shift. All potential trouble for a business that’s still tied closely to government and research demand.

For now, insider sales haven’t shifted the fundamental case for the shares. Investors remain focused on whether Rigetti can convert growing system interest and improved hardware into consistent revenue—before any potential roadmap stumble resets the stock again.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
Gold Price Today Falls as Dollar Rises, but Fed and Oil Shock Keep Bullion in Play
Previous Story

Gold Price Today Falls as Dollar Rises, but Fed and Oil Shock Keep Bullion in Play

Gold Price Today: Bullion Steadies Near $4,400 After Monday’s Violent Selloff
Next Story

Gold Price Today: Bullion Steadies Near $4,400 After Monday’s Violent Selloff

Go toTop